Vertex Pharmaceuticals

Vertex Pharmaceuticals, headquartered in Boston, Massachusetts, is a global biotechnology company that invests heavily in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. Founded in 1989, Vertex initially gained recognition for its pioneering work in structure-based drug design, leading to breakthrough treatments in viral infections.

However, the company is most profoundly celebrated for revolutionizing the treatment of Cystic Fibrosis (CF). Through relentless research and targeted scientific focus, Vertex developed a suite of highly effective CFTR modulators—including Kalydeco, Orkambi, Symdeko, and the triple-combination therapy Trikafta. These groundbreaking therapies target the underlying genetic cause of CF rather than just managing symptoms, fundamentally changing the life expectancy and quality of life for the vast majority of patients living with this devastating disease.

Building on its unprecedented success in CF, Vertex has aggressively expanded its research portfolio into other severe genetic and specialized disorders, including Sickle Cell Disease, Beta Thalassemia, APOL1-mediated kidney disease, and Type 1 Diabetes. Notably, Vertex, in partnership with CRISPR Therapeutics, developed Casgevy, the world’s first approved therapy utilizing CRISPR/Cas9 gene-editing technology, marking a historic milestone in genetic medicine.

The organization operates highly advanced research and development centers in Boston, San Diego, and Oxford, UK, employing top-tier scientific talent. Vertex is characterized by its high-risk, high-reward approach to R&D, focusing only on targets where human biology is fully understood and where the impact on patients will be profoundly transformative. With a rapidly advancing clinical pipeline and a strong commitment to global patient access, Vertex continues to redefine the boundaries of precision medicine.